GAD-alum immunotherapy in type 1 diabetes expands bifunctional Th1/Th2 autoreactive CD4 T cells

AIMS/HYPOTHESIS: Antigen-specific therapy aims to modify inflammatory T cell responses in type 1 diabetes and restore immune tolerance. One strategy employs GAD65 conjugated to aluminium hydroxide (GAD-alum) to take advantage of the T helper (Th)2-biasing adjuvant properties of alum and thereby regu...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Diabetologia
Main Authors: Arif, Sefina, Gomez-Tourino, Iria, Kamra, Yogesh, Pujol-Autonell, Irma, Hanton, Emily, Tree, Timothy, Melandri, Daisy, Hull, Caroline, Wherrett, Diane K., Beam, Craig, Roep, Bart O., Lorenc, Anna, Peakman, Mark
Formato: Artigo
Idioma:Inglês
Publicado em: Springer Berlin Heidelberg 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7228993/
https://ncbi.nlm.nih.gov/pubmed/32248243
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00125-020-05130-7
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados